A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Subscribe To Our Newsletter & Stay Updated
